Charles River Laboratories International (CRL): Director Foster James C sold $8,414,700 worth of shares (24,042 units at $350.00) as part of a pre-agreed trading plan (SEC Form 4)
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for CRL
Across the 30 sessions after earlier CRL headlines, the stock closed higher 15 times and lower 15 times, with a median move of 1.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CRL | SPY |
|---|---|---|---|
| Oct 23, 2026 | Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment | +1.7% | -0.5% |
| Oct 13, 2026 | Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development | -0.9% | -0.0% |
| Oct 9, 2026 | Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call | +1.3% | +0.6% |
| Oct 6, 2026 | Charles River and Autolomous Partner to Transform Laboratory Execution Systems | -1.9% | +0.5% |
| Sep 30, 2026 | UBS resumed coverage on Charles River with a new price target | -0.3% | -0.2% |
| Sep 24, 2026 | Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day | +6.2% | -0.1% |
Earlier insider filings at CRL
- Oct 23, 2026CEVP, Disc & Safety Assessment Parisotto Shannon M sold $742,548 worth of shares (2,156 units at $344.41) as part of a pre-agreed trading plan (SEC Form 4)
- Oct 8, 2026CEVP, Disc & Safety Assessment Parisotto Shannon M sold $302,580 worth of shares (981 units at $308.44) as part of a pre-agreed trading plan (SEC Form 4)
- Oct 2, 2026EVP & Chief Financial Officer Coleman Glenn bought $2,974 worth of shares (10 units at $297.43), increasing direct ownership by 0.04% to 27,762 units (SEC Form 4)
- Aug 27, 2026Director Foster James C exercised 33,561 shares at a strike of $199.42 and sold $10,068,300 worth of shares (33,561 units at $300.00) as part of a pre-agreed trading plan (SEC Form 4)
- Aug 20, 2026Chief Executive Officer Girshick Birgit gifted 528 shares, decreasing direct ownership by 1% to 35,485 units (SEC Form 4)
Quantisnow market dataNYSE
CRL
Charles River Laboratories International Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Listed since
- 2000
Get push alerts for CRL
Full CRL profile on Quantisnow Follow CRL and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time